---
title: NorthernBio vs PharmaLegacy Laboratories
slug_a: northernbiolab
slug_b: pharmalegacy
site: cro
review_signal_gate: closed
canonical_path: /compare/northernbiolab/pharmalegacy
---

# NorthernBio vs PharmaLegacy Laboratories

Side-by-side profile data from each company listing on this directory.

## NorthernBio

- Profile: [/companies/northernbiolab](/companies/northernbiolab)

NorthernBio — Michigan-based preclinical CRO specializing in targeted drug delivery, molecular biology, and bioanalysis with three GLP-compliant facilities supporting non-GLP and GLP safety assessment studies.

Services: 10. Modalities: 0. Indications: 5. Locations: 3. Certifications: 2. The strongest documented coverage currently appears in services (10).

### Services

- Preclinical In Vivo Studies
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- GLP Toxicology
- Specialized & Large-Animal Models
- Bioanalysis
- Ligand-Binding Bioanalysis (Large Molecule)
- Translational Research
- CNS Specialty Services
- Cardiovascular & Metabolic Specialty Services

### Modalities

- Data not yet provided.

### Indications

- Neurology
- Metabolic
- Cardiovascular
- Rare Disease
- Ophthalmology

### Phases

- Preclinical (General)
- Preclinical (IND-Enabling)

### Sourcing models

- Full-Service Outsourcing (FSO)

## PharmaLegacy Laboratories

- Profile: [/companies/pharmalegacy](/companies/pharmalegacy)

PharmaLegacy Laboratories — Preclinical CRO with over 1,500 validated in vivo efficacy models spanning 100+ indications in oncology, immunology, inflammation, and bone disease. AAALAC-accredited vivarium with capacity for 30,000 rodents and 350 non-human primates supports IND filings to FDA and CFDA.

Services: 8. Modalities: 2. Indications: 3. Locations: 1. Certifications: 0. The strongest documented coverage currently appears in services (8).

### Services

- Safety Pharmacology
- Preclinical In Vivo Studies
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- Specialized & Large-Animal Models
- US FDA Regulatory Strategy
- China NMPA Regulatory Strategy
- Translational Research

### Modalities

- Biologics (Monoclonal Antibodies)
- Biologics (Other)

### Indications

- Oncology
- Immunology
- Rare Disease

### Phases

- Preclinical (General)
- Preclinical (IND-Enabling)

### Sourcing models

- Full-Service Outsourcing (FSO)